Nutrition 21 Receives Commitment from CVS/pharmacy for Diachrome(R); Now Available for People with Diabetes at CVS/pharmacy, the First Retailer to Carry Diachrome
Wednesday, February 22, 2006 12:34 ET
PURCHASE, N.Y., Feb 22, 2006 (BUSINESS WIRE) -- Nutrition 21, Inc., (NASDAQ: NXXI) today announced that CVS/pharmacy will be the first retailer to carry the Company's Diachrome(R) product. Diachrome will be available at all 5,400 plus CVS/pharmacy stores in the diabetes area of its home health section. Nutrition 21 is working to secure similar product placements for Diachrome at other major drug retailers.
---
Dutton Associates Announces Investment Opinion: Nutrition 21 Rating Maintained at Strong Buy in Update by Dutton Associates Wednesday January 18, 12:30 pm ET
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Jan. 18, 2006--Dutton Associates continues its coverage of Nutrition 21 (Nasdaq:NXXI - News), maintaining its rating at Strong Buy and a $1.70 target price. The 11-page report by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex, Knobias, and other leading financial portals.
posted
Yep, I am concentrating on these cheap Nasdaqers...The next two months may bring us great staying power as well as exellant liquidity in these stocks..
I plan on a double in my Nasdaqer account over the next 2 months!
Posts: 10729 | From: oregon | Registered: Feb 2005
| IP: Logged |
posted
FLYING on major news...just broke 3 years high
Nutrition 21 Receives Commitment from Two Major Retailers for its Chromax(R) Chromium Picolinate Thursday March 9, 11:35 am ET Food, Drug, Mass Retailer Support Continues to Grow
PURCHASE, N.Y.--(BUSINESS WIRE)--March 9, 2006--Nutrition 21, Inc., (NASDAQ: NXXI - News) today announced that it has received purchase orders from two major national retailers for the company's Chromax® chromium picolinate product in addition to Rite Aid. The customers have requested that the company not announce their names. Chromax is a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism.
"Our new customers are two of the top 10 largest retailers in the United States. Obviously, their commitments are a major milestone in our move to supplying our branded finished products in addition to wholesale ingredients," said Paul Intlekofer, COO of Nutrition 21. "It also reflects growing appreciation by retailers of the appeal that chromium picolinate has to consumers -- chromium is to insulin health as calcium is to bone health. It was one of five featured "Super Nutrients" in the January 16 issue of Newsweek magazine."
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The Company markets Chromax® chromium picolinate, http://www.chromax.com/, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome®, http://www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at http://www.nutrition21.com.
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2005 and subsequent reports on From 10-Q. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
Contact: Nutrition 21, Inc. Maryrose Lombardo, 914-701-4525
Posts: 2691 | Registered: Dec 2003
| IP: Logged |
posted
news out today. order from Albertsons. trying to hold 1.50
Nutrition 21 gets purchase order from Albertson's Thu Mar 23, 2006 2:31 PM ET March 23 (Reuters) - Nutrition 21 Inc. (NXXI.O: Quote, Profile, Research) on Thursday said it received a purchase order from grocer Albertson's Inc. (ABS.N: Quote, Profile, Research) for its supplement which helps improve blood sugar metabolism.
In a news statement, the biosciences company said Albertson's will distribute the Chromax chromium picolinate product at its stores under the banners Albertsons, Sav-on Drugs, Jewel-Osco and OscoDrug. (Reporting by Anup Roy in Bangalore)
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
posted
still looking good. hopefully these deals translate into solid sales growth over the next 6-9 months
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003
| IP: Logged |
Nutrition 21 Receives Commitment from a National Retail Chain for its Chromax(R) Product Monday April 10, 1:19 pm ET Food, Drug and Mass Retailer Support Continues to Grow
PURCHASE, N.Y.--(BUSINESS WIRE)--April 10, 2006--Nutrition 21, Inc., (NASDAQ: NXXI - News) today announced that it has received a purchase order from a national retail chain for the company's Chromax® chromium picolinate product. The Customer has requested that Nutrition 21 not announce its name until the product is available at all of its 5,000 plus stores. The Customer also committed to distribute the Company's Diachrome product. ADVERTISEMENT
Chromax is a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism and cardiovascular health. Diachrome is a non-prescription nutrient based insulin sensitizer for people with type 2 diabetes.
"We now have commitments from five of the top eight retailers in the United States," said Paul Intlekofer, COO of Nutrition 21. "Their commitment to put Chromax on the shelf is further evidence of the growing public interest in the insulin-related benefits of chromium picolinate. Chromium is to insulin health as calcium is to bone health. Chromium picolinate is one of five featured "Super Nutrients" in the January 16 issue of Newsweek magazine. It was also the focus of a feature story in the April 3 issue of First for Women."
The Company is supporting its strategy for direct retail sales of Chromax and the chromium picolinate category with a comprehensive marketing and communications program. The Company expects revenues from its direct retail sales efforts to commence in the 2nd calendar quarter of 2006.
posted
Nutrition 21 Receives Commitment from WellMed to Purchase Diachrome(R) for Patients with Diabetes Tuesday April 18, 1:22 pm ET Diachrome incorporated into clinical guidelines for type 2 diabetes patients
PURCHASE, N.Y. & SAN ANTONIO--(BUSINESS WIRE)--April 18, 2006--Nutrition 21, Inc. (NXXI: NASDAQ) and WellMed Medical Management, Inc. today announced an agreement for a five-year program that will provide Diachrome® to people with type 2 diabetes who participate in WellMed's diabetes disease management program in San Antonio, Texas.
WellMed is a physician-owned practice management company which owns ten clinics and provides management services to 18 additional clinics in the San Antonio area. WellMed will purchase Diachrome directly from Nutrition 21 and provide the product to their participants as a daily nutritional support regimen designed specifically for people with diabetes.
"The WellMed commitment results from our strategy of working directly with healthcare provider groups and disease management organizations to incorporate Diachrome into their treatment protocols," said Paul Intlekofer, COO of Nutrition 21. "WellMed appreciated Diachrome's unique value proposition in addressing a healthcare crisis in the United States. Having participated as a study center in our recently completed 447 subject study conducted with XLHealth, a disease management firm, WellMed's first hand experience with Diachrome led them to make a decision to not only recommend the product, but to buy it directly and provide it to their patients."
"Their commitment further heightens awareness of the safety and efficacy of Diachrome as an adjunct therapy for people with diabetes as we begin with our plan to roll-out Diachrome nationally in major drug chains and also continue to work with other managed care organizations," added Intlekofer.
Diachrome is a non-prescription, nutrient-based insulin sensitizer for adults who have type 2 diabetes that has shown a positive dual effect on blood sugar as well as lipid metabolism in clinical studies and practice. It is a patented composition with United States and international patent protection through 2017.
"We are excited about the opportunity to include Diachrome in our treatment regimen for people with diabetes," said George M. Rapier, III, M.D, CEO for WellMed. "We have seen compelling clinical evidence on Diachrome's safety and efficacy. Including this affordable complementary therapy into our current program will offer our diabetes participants another means of controlling their diabetes while substantially lessening the economic burden of the disease."
As part of the agreement, WellMed has included Diachrome in its clinical guidelines for providing care to patients with diabetes. Diachrome will be delivered initially to 1,500 WellMed patients participating in the WellMed diabetes disease management program. This number is expected to grow as more patients with diabetes are identified and moved into the disease management program and as WellMed's service locations expand. Diachrome is currently available at CVS/pharmacy in the Home Diagnostic/Diabetes Care section.
According to the American Diabetes Association, there are 18.2 million people in the United States, or 6.3 percent of the population, who have diabetes. The economic impact of diabetes was estimated at $132 billion in 2002, including direct medical expenditures and the costs of lost productivity. From 1997 to 2002, the per capita annual cost of diabetes rose 30 percent.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The Company markets Chromax® chromium picolinate, http://www.chromax.com/, which is the most-studied form of the essential mineral chromium. Nutrition 21 also developed Diachrome®, http://www.diachrome.com. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at http://www.nutrition21.com.
About WellMed Medical Management
Established in San Antonio in 1990, WellMed is a physician-owned practice management company managing the operations of medical groups specializing in senior health care services. WellMed owns 10 clinics and provides management services to 18 additional clinics in the San Antonio area. In addition to a focus on senior and disabled patients, WellMed also contracts to provide primary care services to 6,000 San Antonio area veterans. WellMed has been recognized for its early adoption of Electronic Medical Records in its delivery of healthcare to 60,000-plus patients in the San Antonio area. www.wellmedmedicalgroup.com
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2005 and subsequent reports on From 10-Q. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
Contact: Nutrition 21, Inc. Sarah Yeager, 914-701-4506 or Bryan Grundhoefer, 210-617-4702
-------------------------------------------------------------------------------- Source: Nutrition 21, Inc.
posted
News out...confirms deal with WALMART...check middle paragraph.
PURCHASE, N.Y.--(BUSINESS WIRE)--April 26, 2006--Nutrition 21, Inc., (NASDAQ: NXXI - News) today announced that its Board of Directors has elected Paul Intlekofer as president and chief executive officer. Mr. Intlekofer has been serving as chief financial officer and senior vice president of corporate development since January 2003 and most recently was elected chief operating officer in November 2005. ADVERTISEMENT
"Paul Intlekofer's proven leadership and strategic vision have been the driving force behind the company's current transition toward becoming a supplier of branded finished products addressing therapeutic markets," said John Gutfreund, Chairman of the Board. "Mr. Intlekofer possesses a unique mix of strategic vision, passion and operational discipline that has served and will continue to serve Nutrition 21 well. The Board is confident that Mr. Intlekofer is the right person to realize the potential of Nutrition 21."
"I am honored to be selected CEO," said Intlekofer. "I know first hand that we have great products that address significant and growing markets. Over the past several years we've made a considerable investment in research to clinically validate our proprietary technologies. We recently built out an experienced and talented sales and marketing team to capitalize on these findings. Their contribution and pace of execution gives me great confidence in the long-term future and growth of the company."
Since January of 2006, the Company has secured distribution for its Chromax® chromium picolinate in Wal-Mart, Rite Aid, Albertsons, Kroger and another major drug chain. The Company expects to have full nationwide distribution in these and over 90 percent of food, drug and mass outlets by the end of the summer. The Company is also working with the retailers to create an Insulin Health end-benefit destination on the shelf for chromium picolinate similar to Bone Health for calcium.
"With an aging baby boomer population and the rise of obesity there are tens of millions of adults concerned with their blood sugar and cholesterol levels and their risk for developing heart disease and type 2 diabetes. As a natural solution for managing insulin, Chromax can become an everyday product similar to calcium. In the U.S. alone, calcium accounts for $1 billion in retail stand-alone sales," added Intlekofer.
Nutrition 21 also recently secured a commitment from CVS/pharmacy for Diachrome, a non-prescription nutrient based insulin sensitizer for people with type 2 diabetes. The Company expects to have full nationwide distribution of Diachrome with the major drug chains by the Fall to coincide with the publication of its recently completed study with XLHealth.
"The key to success for Diachrome is to secure endorsement and recommendation from pharmacists and healthcare providers. We've taken considerable steps to substantiate Diachrome's health benefits and the early results indicate that physicians are impressed with Diachrome's efficacy and safety. We have developed an innovative marketing strategy that will leverage the managed care/disease management information infrastructure to communicate the benefits of Diachrome to the healthcare community," said Intlekofer.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The Company markets Chromax® chromium picolinate, http://www.chromax.com/, the most-studied form of the essential mineral chromium which is now available through food, drug and mass retailers nationwide. Nutrition 21 also developed Diachrome®, http://www.diachrome.com, a proprietary adjunct nutritional therapy for people with type 2 diabetes. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at http://www.nutrition21.com.
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2005 and subsequent reports on From 10-Q. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
Contact: Nutrition 21, Inc. Maryrose Lombardo, 914-701-4525
-------------------------------------------------------------------------------- Source: Nutrition 21, Inc.
posted
More good news...not showing everywhere yet
Nutrition 21 Receives Commitment from Duane Reade for its Chromax(R) and Diachrome(R) Products; Food, Drug and Mass Retailer Support Continues to Grow
PURCHASE, N.Y.--(BUSINESS WIRE)--May 8, 2006--Nutrition 21, Inc., (NASDAQ: NXXI) today announced that it has received a commitment from Duane Reade, Inc. for the company's Chromax(R) chromium picolinate and Diachrome(R) products. Duane Reade is the largest drug chain in the New York City metropolitan area with 250 plus stores.
Chromax is a supplement for healthy and pre-diabetic people, that promotes insulin health and helps improve blood sugar metabolism, improve cardiovascular health, control carbohydrate cravings and fight weight gain. Diachrome is a non-prescription, nutrient based insulin sensitizer for people with type 2 diabetes.
"Duane Reade's commitment furthers our strategy for national distribution to include the major nationwide chains as well as the largest regional retailers," said Paul Intlekofer, president and CEO of Nutrition 21. "Their commitment to put Chromax on the shelf is further evidence of the growing public interest in the insulin-related benefits of chromium picolinate. Chromium is to insulin health as calcium is to bone health. Chromium picolinate is one of five featured "Super Nutrients" in the January 16 issue of Newsweek magazine. It was also the focus of a feature story in the April 3 issue of First for Women."
The Company is supporting its strategy for direct retail sales of Chromax and the chromium picolinate category with a comprehensive marketing and communications program. The Company is initially launching Diachrome through the major drug chains. The Company expects revenues from its direct retail sales efforts to commence in the 2nd calendar quarter of 2006.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The Company markets Chromax(R) chromium picolinate, http://www.chromax.com/, the most-studied form of the essential mineral chromium which is now available through food, drug and mass retailers nationwide. Nutrition 21 also developed Diachrome(R), http://www.diachrome.com, a proprietary adjunct nutritional therapy for people with type 2 diabetes. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at http://www.nutrition21.com.
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2005 and subsequent reports on From 10-Q. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
posted
NEW YORK, May 17 (newratings.com) - Analyst William R Prather of JM Dutton maintains his "strong buy" rating on Nutrition 21 Inc (ticker: NXXI). The 12-month target price has been raised from $1.70 to $3.30.
In a research note published yesterday, the analyst mentions that the company has been successful in the aggressive pursuit of the commercialization of Chromax and Diachrome. Nutrition 21 has large potential markets, estimated at more than $4 billion, the analyst says. The company possesses extremely good managerial skills and maintains excellent relationships with its customers, including the largest US retailers and drug stores, JM Dutton adds. The analyst expects the company's gross margins to exceed 80% going forward.
posted
Nutrition 21 Raises $10.0 Million in Private Placements
Friday , May 19, 2006 10:14 ET
PURCHASE, N.Y., May 19, 2006 (BUSINESS WIRE) -- Nutrition 21 (NASDAQ: NXXI), the leading developer and marketer of chromium-based nutritional supplements, today announced that it completed separate private placements of 5,555,556 shares of common stock at $1.80 per share for aggregate gross proceeds of $10.0 million. The Company also issued to the investors 2,222,222 five-year warrants that are exercisable at $2.20 per share. The securities were sold pursuant to separate agreements to a select group of institutional and private investors, including Fort Mason Capital LLC and BETA. C.E. Unterberg Towbin, LLC acted as the primary financial advisor to Nutrition 21 in these placements.
The Company intends to use the net proceeds from the sale of these securities primarily for marketing and advertising of Chromax(R) and Diachrome(R), the Company's first branded chromium picolinate-based proprietary products. In addition, a portion of the net proceeds will be allocated to continue to aggressively enforce the Company's patent rights.
Paul Intlekofer, President and Chief Executive Officer of Nutrition 21, said, "The quality of investors in these private placements reflects the confidence we share in our business strategy, as well as the market potential of our products."
Dr. Mitchell Blutt, CEO of BETA, one of the lead investors in this financing, stated, "As a healthcare focused investment firm, the basis of our interest in Nutrition 21 is the strength of its proprietary science and its market potential."
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. The securities have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Nutrition 21 has agreed pursuant to separate registration rights agreements to file a registration statement covering resales by the investors of the common stock sold to the investors and the common stock issuable on exercise of the warrants.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated by clinical research. The company markets Chromax(R) chromium picolinate, http://www.chromax.com/, which is the most-studied form of the essential mineral chromium. Chromax is now available through food, drug and mass retailers nationwide. Nutrition 21 also developed Diachrome(R), http://www.diachrome.com/ , a proprietary adjunct nutritional therapy for people with type 2 diabetes. Nutrition 21 holds 36 patents for nutrition products and uses, 27 of which are for chromium compounds and their uses. More information is available at http://www.nutrition21.com.
Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate," "intend" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended June 30, 2005. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
